相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。First-in-human phase I safety, pharmacokinetic (PK), and pharmacodynamic (PD) analysis of the oral MEK-inhibitor AS703026 (two regimens [R]) in patients (pts) with advanced solid tumors.
J. Delord et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Targeted Therapies for Renal Cell Carcinoma: Review of Adverse Event Management Strategies
Tim Eisen et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2012)
The Expanding Role of Vascular Endothelial Growth Factor Inhibitors in Ophthalmology
Michael W. Stewart
MAYO CLINIC PROCEEDINGS (2012)
Acute intraocular inflammation following intravitreal injection of bevacizumab - a large cluster of cases
Michael Fielden et al.
ACTA OPHTHALMOLOGICA (2011)
Cetuximab-Associated Elongation of the Eyelashes Case Report and Review of Eyelash Trichomegaly Secondary to Epidermal Growth Factor Receptor Inhibitors
Philip R. Cohen et al.
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY (2011)
Beyond VEGF: Inhibition of the Fibroblast Growth Factor Pathway and Antiangiogenesis
Christopher Lieu et al.
CLINICAL CANCER RESEARCH (2011)
Phase 2 trial of linifanib (ABT-869) in patients with advanced renal cell cancer after sunitinib failure
Nizar M. Tannir et al.
EUROPEAN JOURNAL OF CANCER (2011)
Neurosensory retinal detachment due to sunitinib treatment
A. Wegner et al.
EYE (2011)
Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity
Scott M. Wilhelm et al.
INTERNATIONAL JOURNAL OF CANCER (2011)
Trichomegaly and Poliosis of the Eyelashes During Cetuximab Treatment of Metastatic Colorectal Cancer
Nelson A. Rodriguez et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Activity of XL184 (Cabozantinib), an Oral Tyrosine Kinase Inhibitor, in Patients With Medullary Thyroid Cancer
Razelle Kurzrock et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
First-in-human, safety, pharmacodynamic (PD) and pharmacokinetic (PK) trial of a first-in-class dual RAF/MEK inhibitor, RO5126766, in patients with advanced or metastatic solid tumors.
S. O. Dolly et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Phase I (Ph) safety, pharmacodynamic (PD), and pharmacokinetic (PK) trial of a pure MEK inhibitor (i), RO4987655, in patients with advanced /metastatic solid tumor.
S. Leijen et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Safety and evidence of activity of MSC1936369, an oral MEK1/2 inhibitor, in patients with advanced malignancies.
N. Houede et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Phase II Study of the Antibody Drug Conjugate Trastuzumab-DM1 for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2) -Positive Breast Cancer After Prior HER2-Directed Therapy
Howard A. Burris et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
First-in-Man Clinical Trial of the Oral Pan-AKT Inhibitor MK-2206 in Patients With Advanced Solid Tumors
Timothy A. Yap et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial
Brian I. Rini et al.
LANCET (2011)
Management of adverse events associated with tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia
E. Jabbour et al.
LEUKEMIA (2011)
Crizotinib in Anaplastic Large-Cell Lymphoma
Carlo Gambacorti-Passerini et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Efficacy of Intravitreal Bevacizumab for Stage 3+Retinopathy of Prematurity.
Helen A. Mintz-Hittner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Ranibizumab and Bevacizumab for Neovascular Age-Related Macular Degeneration The CATT Research Group
Daniel F. Martin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors.
Eric Raymond et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Drug-Induced Graves Disease From CTLA-4 Receptor Suppression
Gary Borodic et al.
OPHTHALMIC PLASTIC AND RECONSTRUCTIVE SURGERY (2011)
Intravitreal bevacizumab for macular edema due to branch retinal vein occlusion: 12-month results
Mehmet Demir et al.
CLINICAL OPHTHALMOLOGY (2011)
Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral MAPK/ERK Kinase Inhibitor PD-0325901 in Patients with Advanced Cancers
Patricia M. LoRusso et al.
CLINICAL CANCER RESEARCH (2010)
The First-in-Human Study of the Hydrogen Sulfate (Hyd-Sulfate) Capsule of the MEK1/2 Inhibitor AZD6244 (ARRY-142886): A Phase I Open-Label Multicenter Trial in Patients with Advanced Cancer
Udai Banerji et al.
CLINICAL CANCER RESEARCH (2010)
Erlotinib-induced trichomegaly in a male patient with pancreatic cancer
Muhammad Wasif Saif et al.
CUTANEOUS AND OCULAR TOXICOLOGY (2010)
Central serous chorioretinopathy: an update on pathogenesis and treatment
M. Gemenetzi et al.
EYE (2010)
AIDS-Related Kaposi's Sarcoma of the Gastrointestinal Tract
Steven Attia et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Phase I pharmacokinetic and pharmacodynamic evaluation of the vascular disrupting agent OX14503 in patients with advanced solid tumors.
M. Zweifel et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
AUY922, a novel HSP90 inhibitor: Final results of a First-in-human study in patients with advanced solid malignancies.
T. A. Samuel et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Phase I Study of Intravenous Vascular Endothelial Growth Factor Trap, Aflibercept, in Patients With Advanced Solid Tumors
A. Craig Lockhart et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Safety and efficacy results from the first-in-human study of the oral MEK 1/2 inhibitor GSK1120212
J. R. Infante et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial
Cora N. Sternberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
From basic research to clinical development of MEK1/2 inhibitors for cancer therapy
Christophe Fremin et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2010)
Cetuximab-induced hypertrichosis of the scalp and eyelashes
Sergio Vano-Galvan et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2010)
Anaplastic Lymphoma Kinase Inhibition in Non-Small-Cell Lung Cancer
Eunice L. Kwak et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Retinal and Ocular Toxicity in Ocular Application of Drugs and Chemicals - Part II: Retinal Toxicity of Current and New Drugs
Fernando Marcondes Penha et al.
OPHTHALMIC RESEARCH (2010)
A Prospective Randomized Trial of Intravitreal Bevacizumab or Laser Therapy in the Management of Diabetic Macular Edema (BOLT Study) 12-Month Data: Report 2
Michel Michaelides et al.
OPHTHALMOLOGY (2010)
Characteristics of severe intraocular inflammation following intravitreal injection of bevacizumab (Avastin)
M. Georgopoulos et al.
BRITISH JOURNAL OF OPHTHALMOLOGY (2009)
Trichomegaly of the eyelashes following treatment with cetuximab
M. Vaccaro et al.
CLINICAL AND EXPERIMENTAL DERMATOLOGY (2009)
Trichomegaly of the Eyelashes After Colorectal Cancer Treatment With the Epidermal Growth Factor Receptor Inhibitor Cetuximab
Richard Bambury et al.
CLINICAL COLORECTAL CANCER (2009)
Persistent Corneal Epithelial Defect Associated With Erlotinib Treatment
Keegan S. Johnson et al.
CORNEA (2009)
Ocular Side Effects Associated with Imatinib Mesylate and Perifosine for Gastrointestinal Stromal Tumor
S. Serdar Dogan et al.
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA (2009)
A case of trichomegaly of the eyelashes and facial hypertrichosis induced by erlotinib (Tarceva (R))
Gemma Marquez et al.
INTERNATIONAL JOURNAL OF DERMATOLOGY (2009)
Phase I Study of the Humanized Anti-CD40 Monoclonal Antibody Dacetuzumab in Refractory or Recurrent Non-Hodgkin's Lymphoma
Ranjana Advani et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
PD0325901, a Mitogen-Activated Protein Kinase Kinase Inhibitor, Produces Ocular Toxicity in a Rabbit Animal Model of Retinal Vein Occlusion
Wenhu Huang et al.
JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS (2009)
Anterior Uveitis Complicating Zoledronic Acid Infusion
Annalisa Colucci et al.
OCULAR IMMUNOLOGY AND INFLAMMATION (2009)
Transient Retinal Effects of 5,6-Dimethylxanthenone-4-acetic Acid (DMXAA, ASA404), an Antitumor Vascular-Disrupting Agent in Phase I Clinical Trials
Michael B. Jameson et al.
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE (2009)
US Food and Drug Administration approval: Panitumumab for epidermal growth factor receptor-expressing metestetic colorectal carcinoma with progression following fluropyrimidine-, oxelipletin-, and irinotecen-containing chemotherapy regimens
Ruthann M. Giusti et al.
CLINICAL CANCER RESEARCH (2008)
Association of the CTLA-4 gene with Vogt-Koyanagi-Harada syndrome
Liping Du et al.
CLINICAL IMMUNOLOGY (2008)
Persisting corneal erosion under cetuximab (Erbitux) treatment (Epidermal growth factor receptor antibody)
Claudia G. Foerster et al.
CORNEA (2008)
Trichomegaly of the eyelashes after lung cancer treatment with the epidermal growth factor receptor inhibitor erlotinib
Fadi Braiteh et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers
Alex A. Adjei et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Unilateral Anterior Uveitis Complicating Zoledronic Acid Therapy in Prostate Cancer
Frederic Banal et al.
JOURNAL OF RHEUMATOLOGY (2008)
Sorafenib in advanced hepatocellular carcinoma
Josep M. Llovet et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Ulcerative keratitis in gastrointestinal stromal tumor patients treated with perifosine
Debraj Shome et al.
OPHTHALMOLOGY (2008)
Posterior reversible encephalopathy syndrome during sunitinib therapy
R. Cumurciuc et al.
REVUE NEUROLOGIQUE (2008)
A case report: zoledronic acid-induced anterior uveitis
Saadettin Kilickap et al.
MEDICAL ONCOLOGY (2008)
Differential effects of tamoxifen and anastrozole on optic cup size in breast cancer survivors
Alvin Eisner et al.
BREAST CANCER RESEARCH AND TREATMENT (2007)
American society of clinical oncology endorsement of the cancer care Ontario practice guideline on nonhormonal therapy for men with metastatic hormone-refractory (castration-resistant) prostate cancer
Ethan M. Basch et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Cetuximab for the treatment of colorectal cancer
Derek J. Jonker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer
J. Randolph Hecht et al.
CANCER (2007)
Eye complications of cetuximab therapy
B. Melichar et al.
EUROPEAN JOURNAL OF CANCER CARE (2007)
Acquired trichomegaly and symptomatic external ocular changes in patients receiving epidermal growth factor receptor inhibitors - Case reports and a review of literature
Grace Zhang et al.
CORNEA (2007)
Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada clinical trials group
Malcolm J. Moore et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer
Eric Van Cutsem et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Diffuse punctate keratitis in a patient treated with cetuximab as monotherapy
M. V. Karamouzis et al.
ANNALS OF ONCOLOGY (2007)
Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer
David B. Solit et al.
CLINICAL CANCER RESEARCH (2007)
Sorafenib in advanced clear-cell renal-cell carcinoma
Bernard Escudier et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma
Robert J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Newly recognized ocular side effects of erlotinib
Amanda B. Methvin et al.
OPHTHALMIC PLASTIC AND RECONSTRUCTIVE SURGERY (2007)
Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration - Twenty-four-week results of an uncontrolled open-label clinical study
Andrew A. Moshfeghi et al.
OPHTHALMOLOGY (2006)
5,6-Dimethylxanthenone-4-acetic acid in the treatment of refractory tumors: a phase I safety study of a vascular disrupting agent
M McKeage et al.
CLINICAL CANCER RESEARCH (2006)
Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck
JA Bonner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Ocular toxicity during adjuvant chemoendocrine therapy for early breast cancer - Results from International Breast Cancer Study Group Trials
L Gianni et al.
CANCER (2006)
Unilateral anterior uveitis complicating zoledronic acid therapy in breast cancer
NS El Saghir et al.
BMC CANCER (2005)
Imatinib as a cause of cystoid macular edema following uneventful phacoemulsification surgery
I Masood et al.
JOURNAL OF CATARACT AND REFRACTIVE SURGERY (2005)
Trichomegaly of the eyelashes following treatment with cetuximab
O Bouché et al.
ANNALS OF ONCOLOGY (2005)
Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4
P Attia et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies
PM LoRusso et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Erlotinib in previously treated non-small-cell lung cancer
FA Shepherd et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Ocular findings in patients with solid tumours treated with the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in Phase I and II clinical trials
AB Tullo et al.
EYE (2005)
Ocular toxicity related to cetuximab monotherapy in an advanced colorectal cancer patient
G Tonini et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2005)
Periorbital Oedema and epiphora as ocular side effects of imatinib Mesylate (Gleevec)
B Esmaeli et al.
EYE (2004)
Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer
J Rinehart et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
H Hurwitz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma - A new cause of uveitis
MR Robinson et al.
JOURNAL OF IMMUNOTHERAPY (2004)
Ocular side-effects associated with imatinib mesylate (Gleevec®)
FW Fraunfelder et al.
JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS (2003)
Clinical aspects of a phase I trial of 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent
MB Jameson et al.
BRITISH JOURNAL OF CANCER (2003)
5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent: phase I clinical and pharmacokinetic study
GJS Rustin et al.
BRITISH JOURNAL OF CANCER (2003)
Bisphosphonates and ocular inflammation
FW Fraunfelder et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
American society of clinical oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer
BE Hillner et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
American Society of Clinical Oncology clinical practice guidelines: The role of bisphosphonates in multiple myeloma
JR Berenson et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors
GD Demetri et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Severe periorbital edema secondary to STI571 (Gleevec)
B Esmaeli et al.
CANCER (2002)
Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia.
H Kantarjian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Safety and efficacy of imatinib (ST1571) in metastatic gastrointestinal stromal tumours: a phase I study
AT van Oosterom et al.
LANCET (2001)
The epidermal growth factor receptor (EGFR): Role in corneal wound healing and homeostasis
Y Nakamura et al.
EXPERIMENTAL EYE RESEARCH (2001)
分享论文
